Skip to main content

Table 1 Clinical characteristics of lung cancer and COPD patients

From: Levels and prognostic impact of circulating markers of inflammation, endothelial activation and extracellular matrix remodelling in patients with lung cancer and chronic obstructive pulmonary disease

  Lung cancer without COPD Lung cancer with COPD COPD p-value
Number of patients (%) 92 (44.4%) 115 (55.6%) 42  
Age on randomization, y
 median 67.5 65.8 70 p = 0.175
  < 59 23 (25%) 21 (18.3%) 6 (14.3%)
 60–69 35 (38%) 58 (50.4%) 14 (33.3%)
 70+ 34 (37%) 36 (31.3%) 22 (52.4%)
Sex
 Female 41 (45%) 52 (45%) 23 (55%) p = 0.237
 Male 51 (55%) 63 (55%) 19 (45%)
COPD 2017 classification
 II Moderate (FEV1 50–80%)   99 (86.1%) 16 (38%) p < 0.001
 III Severe (FEV1 30–50%)   15 (13%) 18 (43%)
 IV Very severe (FEV1 < 30%)   1 (0.9%) 8 (19%)
Steroids
 Oral No info No info 4 (9.5%)  
 Inhalation No info No info 27 (64.3%)  
 No steroids    11(26.2%)  
Smoking status
 Never 9 (9.8%) 1 (0.9%) 3 (7%) p = 0.016
 Former 57 (62%) 65 (56.5%) 29 (69%)
 Current 26 (28.2%) 49 (42.6%) 10 (24%)
Pack-years smoked among former/current smokers 83 114 39 p = 0.008
  < 30 47 (57%) 44 (39%) 11 (29%)  
 30–39 16 (20%) 28 (25%) 10 (26%)  
 40–49 4 (5%) 20 (18%) 11 (29%)  
 50+ 15 (18%) 22 (19%) 6 (16%)  
No information 1   1  
Never smokers 9 1 3  
Lung cancer histology
 Squamous cell carcinoma 35 (38%) 69 (60%)   p = 0.001
 Adenocarcinoma 57 (62%) 46 (40%)  
Lung cancer stage
 I 46 (50%) 72 (62.6%)   p = 0.105
 II 28 (30%) 25 (21.7%)  
 III 16 (17%) 17 (14.8%)  
 IV 2 (3%) 1 (0.9%)  
 5-year survival 54 (59%) 68 (59%)  
  1. Clinical characteristics. FEV forced expiratory volume